Lenvatinib is an oral tyrosine kinase inhibitor. It can be found on the market under the brand name Lenvima. Lenvatinib has been approved for use in differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma and very recently for the treatment of endometrial cancer. However impressive the advancement is, the extremely high cost builds barriers not only for the p... https://locantotech.com/?p=159884&preview=true